Challenging times lay ahead for the sales departments in the pharma industry. The COVID-19 pandemic will surely not be the first disruption, as recent geopolitical tensions, and economic turmoil show. Agile and adaptive sales enablement is thus a must-have in the coming months and years.

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Is Pharma’s Business Model like McDonald’s? ...

Is Pharma’s business model like McDonald’s? Doing things over & over again without innovation? McDonald’s is famous for its Hamburger University, a training facility at the McDonald’s Corporation global headquarters in Chicago, Illinois. It instructs high-potential restaurant managers in restaurant management. More than 5,000 students attend Hamburger University each year and over 275,000 people have graduated with a degree in Hamburgerology. Sound familiar? Pharma’s training has been on similar lines – hire people continuously and put them through the grind of mugging up essentials of drugs for diseases that the particular company sells. While the McDonald’s model is ideal for its business of replication, it has outlived its utility in healthcare and drug companies are in danger of being reduced to mere suppliers of drugs to new digital platform businesses unless they learn to innovate.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Marketing

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Policies/Sales

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Strategy

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Boehringer Ingelheim India focuses on partnerships in NCD management

Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”

Pharma and the Covid19 Crisis – An Interaction with Sunil Attavar, CMD, Group Pharma

This is the first part of MedicinMan interview series...

How to Harness the Power of Omnichannel Marketing in the Pharma Industry

Pharmaceutical & medical devices Industry is fast adapting to these changes at various levels of the value chain. Billions of dollars are being spent on digital transformation projects ranging from usage of AI & ML in product development, production and predictive maintenance, Blockchain in supply chain and data management & analytics in strategic decision making. This article focuses on Omnichannel marketing, one of the key digital transformations that the industry is learning and implementing at a rapid pace. Omnichannel Marketing: Promise and Possibilities An industry that historically focused all their brand building and market shaping efforts through F2F meetings & medical education programs has started making giant strides in multi-channel strategy now. A digital journey that started with an e-detailing platform has progressed fast by adding brand websites, Approved E-Mails, social media, webinars and other media effectively creating a multi-channel strategy. The only hindside to this is, all these channels work independently, expecting HCPs to find and sort out information themselves.